Home > Cardiology > ACC/WCC 2020 > Vascular Medicine and Thromboembolism > Apixaban offers new perspective for cancer patients in need of anticoagulation

Apixaban offers new perspective for cancer patients in need of anticoagulation

Presented By
Prof. G. Agnelli, University of Perugia, Italy

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ACC 2020
Trial
Phase 3, CARAVAGGIO
Oral apixaban has shown to be non-inferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism (VTE) in the phase 3, open-label, multinational CARAVAGGIO trial [1]. Of interest was that no increase was observed in the risk of major bleeding at the gastrointestinal (GI) sites. These reassuring results, which were simultaneously published in the New England Journal of Medicine, open up opportunities for patients with cancer-associated thrombosis who are eligible for treatment with direct oral anticoagulants (DOACs), including patients with GI cancer [2]. Patients with cancer run a high risk of recurrent VTE and bleeding. Although major guidelines recommend low-molecular-weight heparin and have recently added edoxaban and rivaroxaban, the high risk of bleeding (mainly at GI site...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on